



# Accelerators for Cancer Therapy

### Simon Jolly University College London

### The Body's Cells: Born To Die

### All cells in the body have a pre-programmed lifespan:

- White blood cells: <I day</p>
- Stomach lining: 2 days
- Sperm cells: 3 days
- Platelets: 10 days
- Skin cells: 4 weeks
- Red blood cells: 4 months
- Pancreas cells: I year
- Bone cells: 25-30 years
- Neurons: lifetime
- Egg cells: lifetime

### Cells reproduce through *mitosis* (cell division).

Cells have a built-in selfdestruct mechanism: if the cell becomes abnormal it is programmed to die. This is called *apoptosis*.



### Cell Division & Control

- 2 types of genes regulate cell growth and replication:
  - Oncogenes promote cell growth and reproduction.
  - Tumour suppressor genes inhibit cell division and survival.



- Genetic errors arise from random mutations during mitosis or external carcinogenic agents.
- In a normally functioning cell, apoptosis safeguards the cell against cancer. If significant error occurs, the damaged cell can "self-destruct" through programmed cell death.

### Cancer: Life Uncontrolled

- For cancer to occur, several errors must occur in sequence:
  - A mutation in the error-correcting machinery of a cell might cause that cell and its children to accumulate errors more rapidly.
  - A further mutation in an oncogene might cause the cell to reproduce more rapidly and more frequently than its normal counterparts.
  - A further mutation may cause loss of a tumour suppressor gene, disrupting the apoptosis signalling pathway and resulting in the cell becoming immortal.
  - A further mutation in signalling machinery of the cell might send error-causing signals to nearby cells.
- At this stage the cell begins to divide uncontrollably: this is cancer.



### Cancer Types & Survival Rates



|       |                             |  |                             | Women | Pancreas           | 2%           |
|-------|-----------------------------|--|-----------------------------|-------|--------------------|--------------|
| Men   | Testis                      | estis 95%                                |                             |       | Lung               | 6%           |
|       | Hodgkin's lymphoma          |  | 84%                         |       | Oesophagus         | 8%           |
|       | Melanoma                    |  | 78% More than 50%           |       | Stomach            | 13%          |
|       | Bladder                     |  | 71% survival:               |       | Brain              | 15%          |
|       | Larynx                      | 6  | 7% 38% of cases             |       | Multiple myeloma   | 22%          |
|       | Prostate                    | 61%                                      | diagnosed                   |       | Ovary              | 34%          |
|       | NHL                         | 51%                                      |                             |       | Leukaemia          | 36%          |
|       | Colon                       | 40%                                      |                             |       | Kidney             | 43%          |
|       | Kidnov                      | 45%                                      | 10-50% survival:            |       | Colon              | 45%          |
|       | l eukaemia                  | 38%                                      | 29% of cases diagnosed      |       | Pectum             | 40%          |
|       | Multiple myeloma            | 24%                                      |                             |       | NUI                | +0 /0<br>52% |
|       | Brain                       | 13%                                      |                             |       | Bladdor            | 5270<br>610/ |
|       | Stomach                     | 12%                                      |                             |       |                    | 0170         |
|       | Oesophagus                  | 7%                                       | less than 10% survival:     |       |                    | 00%          |
|       | Lung                        | 6%                                       | 24% of cases diagnosed      |       | Uterus             | 76%          |
|       | Pancreas                    |  | 000/                        |       | Breast             | 79%          |
| Women | Welanoma                    | 90%                                      |                             |       | Hodgkin's lymphoma | 83%          |
|       | Roost                       |  | 70% More than 50% survival: |       | Melanoma           | 90%          |
|       | Uterus                      | 76% 50% of cases diagnosed<br>68%<br>61% |                             | Men   | Pancreas           | 3%           |
|       | Cervix                      |  |                             |       | Lung               | 6%           |
|       | Bladder                     |  |                             |       | Oesophagus         | 7%           |
|       | NHL                         | <u> </u>                                 |                             |       | Stomach            | 12%          |
|       | Rectum                      | 48%                                      |                             |       |                    | 13%          |
|       | Colon                       | 45%                                      |                             |       | Multiple myeloma   | 24%          |
|       | Kidney                      | 43%                                      | 43% 10-50% survival:        |       | Leukaemia          | 38%          |
|       | Leukaemia                   | 36%                                      | 27% of cases diagnosed      |       | Kidney             | 45%          |
|       | Multiple myoloma            | 22%                                      |                             |       | Rectum             | 45%          |
|       | Rrain                       | 15%                                      |                             |       | Colon              | 46%          |
|       | Stomach                     | 13%                                      |                             |       | NHL                | 51%          |
|       | Oesophagus                  | 8%                                       |                             |       | Prostate           | 61%          |
|       | Lung                        | 6%                                       | less than 10% survival:     |       | Larvnx             | 67%          |
|       | Pancreas                    | 2%                                       | 15% of cases diagnosed      |       | Bladder            | 71%          |
|       | Five-year relative survival |  |                             |       | Melanoma           | 78%          |
|       |                             |  |                             |       | Hodakin's lymphome | 84%          |
|       |                             |  |                             |       | Testis             | 95%          |
|       |                             |  |                             |       | 10010              | 0/0          |

### Cancer Treatment: Cures



### How Radiotherapy Kills Cancer





Simon Jolly — University College London



### Radiotherapy Treatment Room



# IMRT: Intensity Modulated Radiotherapy **UCL**



### Radiotherapy: Energy Deposition





**UCL** 





Simon Jolly — University College London

### The Bragg Peak





Simon Jolly — University College London

## A Real Bragg Peak in Liquid Scintillator **UCL**



#### Simon Jolly — University College London

### Spread-Out Bragg Peak (SOBP)



The original picture from R. R. Wilson's paper on proton therapy. (*Radiology* **47**, 487–491, 1946)

#### Intrinsic - straggling

Deliberate – range modulating

### **Double Scattering**



- Beam passes through range-shifter wheel that modulates the proton beam energy to reach front/back of target volume.
- Scatterer enlarges beam to cover whole volume.
- Collimator shapes outer edge of beam to target area.
- Compensator adds further absorption to reduce energy of protons in certain areas and match delivered beam to **distal** edge of tumour (**not** conformal).

Simon Jolly — University College London

### Clatterbridge Cancer Centre



#### Pencil Beam Scanning



- Pencil beam scanning allows better conformal dose to be delivered to target volume.
- Beam delivered in small "pencil" beams and scanned across target.
- Energy modulated by accelerator: target subdivided into layers and "painted" by using energy variation.

Simon Jolly — University College London

# 









Simon Jolly — University College London

## 



Simon Jolly — University College London

Zhang X, Li Y, Pan X, et al. Int J Radiat Oncol Biol Phys. 2009;77(2):357-366

# Protons Vs. Photons: NSC Lung Cancer



#### Forces

- 2 forces available for accelerating a charged particle:
  - Electric (E)  $F = q\vec{E} + q\left(\vec{v}\times\vec{B}\right)$
  - Magnetic (B)
- Electric field only accelerates in one direction: no continuous bending.
- Magnetic field only accelerates perpendicular to particle velocity: no linear acceleration.
- Use Electric fields for acceleration, magnetic fields for bending/steering/focussing.
- Can relate magnetic force to centripetal acceleration:

$$F = q\left(\vec{v} \times \vec{B}\right) = \frac{m_0 \gamma v^2}{\rho} = \frac{pv}{\rho}$$

• The Magnetic rigidity relates bending radius  $\rho$  to momentum p, magnetic field B and charge q:  $B\rho$ 

#### Cyclotrons



In a classic cyclotron the particles are accelerated by the electric field between the DEE's and permanently deflected by the magnetic field. For  $\omega_{HF} = \omega_c$  this process is resonant as long as the mass is constant (typ. v < 0.15 c).

20/02/14

### Cyclotron Acceleration (I)



### Cyclotron Acceleration (2)



### Cyclotron Acceleration (3)



### Cyclotron Acceleration (4)



### Cyclotron Acceleration (5)



### Cyclotron Acceleration (6)



### Cyclotron Acceleration (7)



### Cyclotron Acceleration (8)



### Cyclotron Acceleration (9)



### Cyclotron Acceleration (10)



### Cyclotron Acceleration (11)



### Cyclotron Acceleration (12)



### Cyclotron Acceleration (13)



### Cyclotron Acceleration (14)



### Cyclotron Acceleration (15)



Simon Jolly — University College London
#### Cyclotron Basics

# **UCL**

- Cyclotron invented in 1929 by E.O. Lawrence.
- Central ion source generates particles and introduces them into the center of the magnetic field where they begin their path.
- The cyclotron is tuned to accelerate one specific mass of particle to a given energy, governed by Bρ.
- Once the particles reach their desired energy at the outer edge of the magnetic field, they can no longer be contained and will be extracted.
- Cyclotrons still used in HEP (TRIUMF 500 MeV cyclotron shown here) but superseded by synchrotrons...





#### **Extraction: Septum Magnets**

# Septum turns small spatial separation into large spatial separation.

- Beam split into 2 paths depending on which side of the septum it is.
- Can either be electrostatic or magnetic.







### Cyclotrons For Proton Therapy

- Cyclotrons are by far the most common accelerator for proton therapy.
- Accelerates beam to single energy, then reduces energy as required:
  - Degrader (absorber/wedges)
  - Energy Selection System (ESS): beamline that selects correct energy.
- If *pulsed beam* is required (eg. spot scanning), keep accelerator as-is and pulse high voltage on ion source.





#### Degraders

- Degraders are needed in cyclotrons to provide variable energy.
- Series of wedges allow multiple energies to be selected.
- Sounds slow, but mechanical movement still allows rapid energy change (100 ms).
- Degrader increases the emittance of the beam:
  - Beam size increases due to multiple scattering.
  - Energy spread increases.
  - Beam loss due to nuclear reactions in the degrader.
- Beam intensity is strongly reduced.
- Need Energy Selection System to select correct energy and clean up beam.





#### Synchrotrons

## UCL

- Synchrotrons take opposite approach:
  - Fix particle radius.
  - Increase magnetic field.
  - Adjust RF frequency to match particles as they get faster.
  - Synchrotron because strength of magnetic field and frequency, amplitude and phase of RF and focussing strength of the lenses have to be synchronised.
- Dipole magnets to bend particles round in circle, and to inject and extract the beam.
- RF electric fields to accelerate particles particle passes accelerating cavities many times.
- Instead of large single vacuum chamber, evacuated volume much smaller:
  - Narrow beam pipe with discrete components.
  - Focussing magnets contain 99.9% of injected beam (more like 50% for cyclotrons!)
- Normally consist of short straight accelerating/focussing/diagnostic sections, separated by bending sections with dipoles.
- B = 0 not possible and therefore a nonzero initial energy is necessary: chain of accelerators.





#### Synchrotrons: Injector



Injector takes beam from ion source, focuses it down to correct size and accelerates it to 7 MeV. Need to do this with a linac as space charge within beam requires rapid acceleration and continuous focussing.

#### Synchrotrons: Injector



Injector takes beam from ion source, focuses it down to correct size and accelerates it to 7 MeV. Need to do this with a linac as space charge within beam requires rapid acceleration and continuous focussing.

#### Synchrotrons: LEBT



Low Energy Beam Transport (LEBT) transports beam from Drift Tube Linac (DTL) exit to synchrotron injection. Consists of several quadrupole doublets for focusing, steering dipoles, beam position monitors and a debuncher to match the beam to synchrotron frequency.

Simon Jolly — University College London

â

#### Synchrotrons: LEBT



Low Energy Beam Transport (LEBT) transports beam from Drift Tube Linac (DTL) exit to synchrotron injection. Consists of several quadrupole doublets for focusing, steering dipoles, beam position monitors and a debuncher to match the beam to synchrotron frequency.

Simon Jolly — University College London

â

#### Synchrotrons: Acceleration (1)



#### Synchrotrons: Acceleration (1)



#### Synchrotrons: Acceleration (2)



Beam begins circulating at 7 MeV...

#### Synchrotrons: Acceleration (3)



Accelerating cavity switches on. Beam accelerated once per turn...

#### Synchrotrons: Acceleration (4)



Simon Jolly — University College London

#### Synchrotrons: Acceleration (5)



Accelerating once per turn...

#### Synchrotrons: Acceleration (6)



Simon Jolly — University College London

#### Synchrotrons: Acceleration (7)



Accelerating once per turn...

#### Synchrotrons: Acceleration (8)



Simon Jolly — University College London

#### Synchrotrons: Acceleration (9)



Accelerating once per turn...

#### Synchrotrons: Acceleration (10)



Simon Jolly — University College London

#### Synchrotrons: Extraction (1)



#### Synchrotrons: Extraction (2)



#### **Extraction: Resonances**

- Resonances play a big part in keeping the beam in a synchrotron.
- Because the beam has to follow the same trajectory, field errors in magnets can add up and the beam can be lost.
- To avoid these resonances, the "tune" – how many revolutions it takes to get the beam back to the same position – is always a non-integer, so field errors do not sum catastrophically.
- Sometimes we *want* to excite a resonant: this can be used for beam extraction.



#### Gantries

- Gantries deliver beam from accelerator to patient.
- A rotating beam transport line
  - Virtually always a single axis.
  - Focuses and directs particle beam to desired location in target volume, at any angle.
  - Gantry rotation + patient table rotation = full solid angle coverage.
- Patient is supine and stationary: setup before beam delivery on robotic couch.
- Components:
  - Mechanical structure and drive.
  - Beamline components: dipoles, quadrupoles, correctors, vacuum, diagnostics.
  - Nozzle: scattering or scanning.
  - Infrastructure.
- Large structures! Frequently above 200 tonnes, 10 m diameter.



#### PSI Gantry 2



## NIRS Superconducting Gantry (2)



### Heidelberg Gantry: I3 m x 22 m





Simon Jolly — University College London



http://www.klinikum.uni-heidelberg.de/HIT-Bildergalerie.114799.0.html

▲ UCL

#### **FFAG** Accelerators

# **UCL**

- Fixed Field Alternating Gradient accelerators (FFAGs) are a combination of synchrotron and cyclotron.
- Field is fixed (like cyclotron) but RF varies (like synchrotron).
- Beam orbit radius increases with energy (like cyclotron), but confined to single (large) beampipe (like synchrotron).
- Taper on dipole pole pieces leads to increasing B-field with radius for simplest scaling version.
- Non-scaling version uses more complex magnet geometries to reduce size of beampipe.
- Allows FAST acceleration cycles (kHz) but with variable energy and fast energy variation since magnets do not need to be ramped.
- Need a matching gantry...



Simon Jolly — University College London



#### Treatment Room



#### Treatment Room



#### Treatment Room







# Spare Slides

Simon Jolly — University College London

#### **UK Proton Therapy**

- Currently UK only has I proton therapy centre: Clatterbridge (Wirral) treats eyes with 60 MeV protons.
- Around 20 existing proton therapy centres worldwide with around the same number planned.
- Most countries treat private patients with simple tumours (85% prostate...).
- Some British children sent abroad for treatment in Jacksonville, FL.
- Earlier this year, government gave the go ahead for 2 new cancer treatment facilities using protons:
  - UCLH.
  - Manchester/Christie.
- Procurement began 2013, up and running in 5 years.

#### PATIENTS TREATED WITH CHARGED PARTICLES, BY COUNTRY



http://www.symmetrymagazine.org/article/september-2014/accelerating-the-fight-against-cancer

### **UK Proton Therapy Indications**

- Indications list is available on the web:
  - Strategic Outline Case: <u>https://</u> www.gov.uk/government/uploads/ system/uploads/attachment\_data/file/ 213045/national-proton-beam-therapyservice-development-programme-valuefor-money-addendum.pdf
  - Value-for-money Addendum: <u>https://</u> www.gov.uk/government/uploads/ system/uploads/attachment\_data/file/ 213045/national-proton-beam-therapyservice-development-programme-valuefor-money-addendum.pdf
- Will treat most difficult cases:
  - Brain: Chordoma, Glioma, Craniopharyngioma, Meningioma, Intracranial Germinoma
  - Skeletal: Chondrosarcoma, Rhabdomyosarcoma, Osteosarcoma, Ewings sarcoma,
  - Central Nervous System: Ependymoma, Medulloblastoma (PNET), Spinal Sarcoma
  - Head & Neck: Retinoblastoma, Nasopharynx, Acoustic Neuroma
  - Others: Hodgkins

|            |                                    | Number<br>of |
|------------|------------------------------------|--------------|
|            | Indication                         | patients     |
| Paediatric | Chordoma/ Chondrosacoma            | 15           |
|            | Rhabdomyosarcoma (Orbit)           | 5            |
|            | Rhabdomyosarcoma (Prameningeal and |              |
|            | H&N)                               | 15           |
|            | Rhabdomysarcoma( Pelvis)           | 10           |
|            | Osteosarcoma                       | 3            |
|            | Ewings                             | 9            |
|            | PPNET                              | 5            |
|            | Ependymoma                         | 25           |
|            | Low Grade Glioma                   | 5            |
|            | Optic Pathway Glioma               | 12           |
|            | Craniphayngioma                    | 15           |
|            | Medulloblastoma (PNET)             | 70           |
|            | Hodgkins                           | 5            |
|            | Retinoblastoma                     | 5            |
|            | Meninggioma                        | 3            |
|            | Intracranial germinoma             | 10           |
|            | Nasopharynx (H&N)                  | 15           |
|            | Difficult Cases Esthe/Neuro/Liver) | 5            |
|            | Very Young Age                     | 20           |
|            | Total                              | 252          |
|            |                                    |              |
| Adult      | Choroidial Melanoma                | 100          |
|            | Ocular/Orbital                     | 25           |
|            | Chordoma                           | 60           |
|            | Chondrosarcoma                     | 30           |
|            | Para- Spinal / Spinal Sarcoma      | 120          |
|            | Sacral Chordoma                    | 60           |
|            | Meningoma                          | 100          |
|            | Acoustic Neuroma                   | 100          |
|            | Craniospinal NOS (Pineal)          | 10           |
|            | Head & Neck & Paranasal Sinuses    | 300          |
|            | PNET(medulloblastoma Intracranial) | 30           |
|            | Difficult cases                    | 300          |
|            |                                    |              |
|            | Total                              | 1,235        |
|            |                                    |              |
|            | GRAND TOTAL                        | 1.487        |

#### UCLH Cancer Campus





- 46-60 HUNTLEY STREET
- (17) MAPLE HOUSE FLATS
- (18) PAUL'S HOUSE (CLIC SARGENT)
- (19) PROPOSED PATIENTS' HOTEL 170 TOTTENHAM COURT ROAD
- (20) WHITFIELD STREET LABORATORIES
- (21) BONHAM CARTER HOUSE / WARWICKSHIRE HOUSE



Simon Jolly — University College London

(21

### UCLH Proton Therapy Site

Rhino

≜UCL

- New facility will be on existing UCLH site, next to Tottenham Court Road.
- Linked to UCLH via walkways to allow easy patient transfer.
- Planning to treat ~750 patients a year.
- I proton accelerator feeding 4 gantries (plus research room).
- Total cost: £150 million.



therapy site

Bentham

Building
### **UCLH PBT Site**





Simon Jolly — University College London

## UCLH PBT Cut-through (Old)



# UCLH PBT Building





## UCLH PBT External



# UCLH PBT (TCR/Grafton Way)



# UCLH PBT (Grafton Way)





### Down Comes The Rosenheim...





Simon Jolly — University College London

